Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Neoadjuvant Sonidegib Active in High-Risk Prostate Cancer

December 2nd 2017

In a study of neoadjuvant sonidegib in men with high-risk localized prostate cancer undergoing prostatectomy, hedgehog pathway activity was detectable at baseline.

Sensitivity, Resistance of Molecular Subtypes in Prostate Cancer Identified Through Drug Response Scores

December 2nd 2017

Prostate cancer has recently been recognized as a genomically heterogeneous disease with subtypes similar to breast or ovarian cancers.

Radium-223/Abiraterone Phase III mCRPC Trial Unblinded

December 2nd 2017

The phase III ERA223 trial exploring radium-223 dichloride plus abiraterone acetate in patients with asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer has been unblinded early.

MRI, PCA3 Tests Are Reliable Indicators of Prostate Biopsy Positivity

December 1st 2017

Both magnetic resonance imaging and prostate cancer antigen 3 tests can predict a positive prostate biopsy and are helpful in identifying high-risk prostate cancer.

Dr. Zhang on the ARCHES Trial in Prostate Cancer

December 1st 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

Radium-223 Retreatment Shows Promise in mCRPC

November 22nd 2017

A second course of radium-223 was associated with minimal hematologic toxicity and low radiographic bone progression rates in a phase I/II study of men with metastatic castration-resistant prostate cancer.

Challenges in mCRPC Landscape Surround Sequencing, Biomarkers, and PARP Inhibition

November 22nd 2017

Tanya B. Dorff, MD, discusses several important components regarding metastatic castration-resistant prostate cancer treatment, including the addition of novel drugs, optimal therapeutic sequences, and the identification of predictive biomarkers.

Dr. Berry on Novel Imaging Techniques for Prostate Cancer

November 22nd 2017

William R. Berry, MD, medical oncologist, Duke University, discusses novel imaging techniques for patients with prostate cancer.

EU Approves Abiraterone for Newly Diagnosed Hormone-Sensitive Prostate Cancer

November 22nd 2017

The European Commission has approved abiraterone acetate (Zytiga) in combination with prednisone/prednisolone for the treatment of adult men with newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer.

Expert Shares Insight on Role of RT, Surgery in Prostate Cancer

November 21st 2017

Jonathan Warner, MD, discusses the evolving role of surgery and radiation therapy in the treatment landscape for patients with prostate cancer.

Dr. Mason on the Significance of the PROTECT Study in Prostate Cancer

November 18th 2017

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in prostate cancer during the 2017 EMUC Congress.

LDH a Predictor for OS in mCRPC Following Radium-223

November 18th 2017

Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.

PI-RADS Offers Prognostic Advantage Over mpMRI Alone for Prostatectomy

November 17th 2017

Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.

PARP Inhibitor Tested in mCRPC

November 17th 2017

Rucaparib, a drug approved for the treatment of ovarian cancer, might also be used to treat patients with metastatic castration-resistant prostate cancer.

Dr. Warner on the Future of Surgery for Patients With Prostate Cancer

November 17th 2017

Jonathan N. Warner, MD, reconstructive urologist, City of Hope, discusses the future of surgery for patients with prostate cancer.

Dr. Dorff on Current Agents for Patients With mCRPC

November 16th 2017

Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Oh on the Management of Hormone-Sensitive Prostate Cancer

November 15th 2017

William Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the management of patients with hormone-sensitive prostate cancer.

Prostate Cancer Paradigm Expanding With Ongoing Research

November 15th 2017

Przemyslaw W. Twardowski, MD, discusses a variety of factors to consider when treating patients with prostate cancer.

Expert Discusses Degarelix and Other Developments in Prostate Cancer

November 14th 2017

Guru P. Sonpavde, MD, discusses degarelix, androgen-deprivation therapy, and ongoing trials with immunotherapy that are crucial to advancing the treatment of patients with prostate cancer.

Pal Shares Insight on Abundance of Options in GU Malignancies

November 14th 2017

Sumanta K. Pal, MD, discusses advancements in prostate cancer, bladder cancer, and promising results in kidney cancer.